Arizona Biomedical Research Commission

Philip Morris Products S.a.

The Arizona Disease Control Research Commission

Arizona Board of Regents, a Body Corporate

Other

University of Alberta

Blairex Laboratories Inc.

Seth David Rose

Rosemarie F Hartman

Karl J Okolotowicz

Scott R Lefler

Steven R Ottersberg

Jed E Rose

James Edward Turner

Thangaraju Murugesan

Ann Y Kim

Dale E Robinson

Jason Houtchens

Peter Williams

Mark A Hayes

Vincent B Pizziconi

Linda J Reha-Krantz

Karce Daniel Rose

K Daniel Rose

Neil Kempton Stone

Linda B Bloom

Cathryn M Rose

Carmen Chow

William H Drummond

A method and apparatus for comfortably, rapidly, and inexpensively collecting a sample from one or more test subjects and analyzing it, singly or pooled with other samples, for presence of SARS-CoV-2. Saliva, nasal drainage, or other body fluids may be collected from one or more test subjects and examined by means of fluorimetry. Mass rapid screening for SARS-CoV-2 is a valuable public health tool to reduce the transmission of COVID-19 while permitting business activity to resume.

Method and apparatus for rapid detection of SARS-CoV-2

The disclosure relates to a method of enhancing nicotine or other medicament concentrations in a gaseous carrier. The methods are adaptable to the delivery of nicotine or other medicaments for therapeutic effect in various diseases, in particular nicotine for tobacco product use cessation, substitution and/or harm reduction. The disclosure further relates various devices and device design principles for practicing these methods.

Device and method for delivery of a medicament

The disclosure relates to an improved method of enhancing nicotine concentrations in a gaseous carrier. The methods are adaptable to the delivery of nicotine for therapeutic effect in various diseases, in particular nicotine for tobacco product use cessation, substitution and/or harm reduction. The disclosure further relates various devices and device design principles for practicing these methods.

The invention relates to devices and methods for delivering nicotine and/or other alkaloids from tobacco, other plants and other natural sources. More particularly, the invention relates to devices and methods for delivering an aerosol of nicotine to a user's lungs without combustion of the nicotine source materials.

Tobacco-based nicotine aerosol generation system

Antimitotic agents comprising a modified chalcone or modified chalcone derivative are disclosed. The modified chalcone or modified chalcone derivative compounds are of the general formula CHAL-LIN-COV, wherein CHAL is a chalcone or chalcone derivative portion, LIN is an optional linker portion, and COV is a covalent bonding portion (e.g., an &#x3b1;,&#x3b2;-unsaturated thiol ester group). The modified chalcone or modified chalcone derivative compounds provide an improved method of interference with tubulin polymerization, for example by covalent (and essentially irreversible) bonding between tubulin and the covalent bonding portion, potentially resulting in a decrease in tumor size and/or disappearance of the cancer, to the benefit of cancer patients.

Modified chalcone compounds as antimitotic agents

Conjugated nitro alkene compounds hamper or prevent proliferation of cancer cells in cell culture and in cancer patients, which can result in a decrease in tumor size and/or disappearance of the cancer. The compounds may act by interference with cancer cell biochemistry, in which isoprenoid groups such as farnesyl and geranylgeranyl become bonded to various oncogenic proteins such as Ras, RhoA, RhoB, or some other growth-related cellular protein(s).

Conjugated nitro alkene anticancer agents based on isoprenoid metabolism

Oncoproteins such as Ras and RhoB are known to induce cell division in an unrestrained manner when such proteins are localized at the inner surface of a cancer cell membrane. The localization is effected by the prenylation reaction, whereby a hydrophobic group (e.g. a farnesyl group) is attached to the protein in the presence of an enzyme (e.g. farnesyl protein transferase). Deactivation of the prenylation enzyme through covalent modification can therefore ultimately result in the mitigation and/or cessation of cancer cell growth. Various prenylation inhibitors having the necessary structural groups to bond covalently, or essentially irreversibly, to the prenylation enzyme include carbonyl or thiocarbonyl compounds (or masked versions of these compounds) and alpha oxo-epoxides bonded to a hydrophobic, substrate-mimicking group. The carbonyl or thiocarbonyl compounds also contain a nucleofugal atom or group to enhance the tendency to form covalent bonds.

Anticancer agents based on regulation of protein prenylation

Antimitotic agents comprising a modified chalcone or modified chalcone derivative are disclosed. The modified chalcone or modified chalcone derivative compounds are of the general formula CHAL-LIN&#x2014;COV, wherein CHAL is a chalcone or chalcone derivative portion, LIN is an optional linker portion, and COV is a covalent bonding portion (e.g., an &#x3b1;,&#x3b2;-unsaturated thiol ester group). The modified chalcone or modified chalcone derivative compounds provide an improved method of interference with tubulin polymerization, for example by covalent (and essentially irreversible) bonding between tubulin and the covalent bonding portion, potentially resulting in a decrease in tumor size and/or disappearance of the cancer, to the benefit of cancer patients.

Methods and compositions for forming protective and/or medicated films on body tissue. Liquid compositions contain a hydrophobically modified polymer, other than an esterified lower-hydroxyalkyl-substituted cellulose, suspended or dissolved in a solvent. The modified polymer is soluble in the solvent but insoluble in body fluids. The compositions may optionally contain a separate medicinal component, i.e., one which is present in addition to any medications, if any, present in the solvent, in the modified polymer and in any other additive components such as flavors, skin penetrants, preservatives, other solvents for the additives, etc. A protective and/or medicated film is formed in situ upon body tissue by applying the liquid composition to the tissue and separating the solvent from the composition, e.g., by vaporization.

Method and compositions for in situ formation of protective and/or medicated films on body tissue

Prenylating enzymes are involved in modifying oncoproteins, such as RAS, so that growth of neoplastic cells becomes uncontrolled. Inactivation of such enzymes can prevent uncontrolled growth. &#x3b1;-Dicarbonyl compounds can be used to covalently modify and thereby inactivate prenylating enzymes such as protein farnesyltransferase and protein geranylgeranyltransferase. The compounds can be designed to enhance affinity and/or specificity for a particular protein substrate.

Anticancer agents based on prevention of protein prenylation

The present invention relates to a novel method for analyzing nucleic acid sequences based on real-time detection of DNA polymerase-catalyzed incorporation of each of the four nucleotide bases, supplied individually and serially in a microfluidic system, to a reaction cell containing a template system comprising a DNA fragment of unknown sequence and an oligonucleotide primer. Incorporation of a nucleotide base into the template system can be detected by any of a variety of methods including but not limited to fluorescence and chemiluminescence detection. Alternatively, microcalorimetic detection of the heat generated by the incorporation of a nucleotide into the extending template system using thermopile, thermistor and refractive index measurements can be used to detect extension reactions.

Growing community of inventors

Tempe, AZ, United States of America

Seth David Rose